Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
第3相
完了
NCT03088540
| 対象疾患 | Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Regeneron Pharmaceuticals |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 712 名 |
|---|
| 介入（薬剤） | Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin |
|---|
| 開始日 | 2017年5月29日 |
|---|
| 完了日 | 2025年4月18日 |
|---|
| 結果公開日 | 2026年6月25日 |
|---|
概要
The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
Overall Survival (OS)
Up to 94 months · months
| Cemiplimab | 23.4 months |
|---|
| Chemotherapy | 13.7 months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.661 (95% CI 0.553–0.790) |
|---|
Progression-free Survival (PFS) Per Blinded IRC
Up to 94 months · months
| Cemiplimab | 6.3 months |
|---|
| Chemotherapy | 5.3 months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.559 (95% CI 0.469–0.665) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。